Exploratory Objectives:~To explore selected biomarkers in peripheral blood and tumor samples that potentially correlate with clinical response to X4P-001 and toriplimab combination treatment~To characterize the antitumor activity of X4P-001 in combination with toriplimab in patients with locally advanced or metastatic TNBC(according to iRECIST 1.1)
Objectives Phase 1b~Primary Objectives:~To evaluate the safety and tolerability of X4P-001 combined with toriplimab in patients with locally advanced or metastatic TNBC~Secondary Objectives:~To characterize the pharmacokinetics (PK) profile of X4P-001 alone or combined with toriplimab~To characterize the antitumor activity of X4P-001 in combination with toriplimab in patients with locally advanced or metastatic TNBC(according to RECIST 1.1)~To characterize the overall survival of X4P-001 in combination with toriplimab in patients with locally advanced or metastatic TNBC~To characterize the immunogenicity of toriplimab when administrated in combination with X4P-001